A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year

J Infect Dis. 2022 Aug 15;226(Suppl 2):S195-S212. doi: 10.1093/infdis/jiac201.

Abstract

Background: The burden and health care utilization (HCU) of respiratory syncytial virus (RSV) in US infants aged <1 year across health care settings are not well characterized.

Methods: We systematically reviewed studies of RSV and bronchiolitis published 2000-2021 (data years, 1979-2020). Outcomes included RSV hospitalization (RSVH)/bronchiolitis hospitalization rates, emergency department (ED)/outpatient (OP) visit rates, and intensive care unit (ICU) admissions or mechanical ventilation (MV) use among RSV-/bronchiolitis-hospitalized infants. Study quality was determined using standard tools.

Results: We identified 141 good-/fair-quality studies. Five national studies reported annual average RSVH rates (range, 11.6 per 1000 per year among infants aged 6-11 months in 2006 to 50.1 per 1000 per year among infants aged 0-2 months in 1997). Two national studies provided RSVH rates by primary diagnosis for the entire study period (range, 22.0-22.7 per 1000 in 1997-1999 and 1997-2000, respectively). No national ED/OP data were available. Among 11 nonnational studies, RSVH rates varied due to differences in time, populations (eg, prematurity), and locations. One national study reported that RSVH infants with high-risk comorbidities had 5-times more MV use compared to non-high-risk infants in 1997-2012.

Conclusions: Substantial data variability was observed. Nationally representative studies are needed to elucidate RSV burden and HCU.

Keywords: RSV; emergency department; infants; intensive care unit admission; lower respiratory tract infection; mechanical ventilation; outpatient; respiratory syncytial virus; respiratory syncytial virus hospitalization; systematic literature review.

Publication types

  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchiolitis* / epidemiology
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Palivizumab
  • Patient Acceptance of Health Care
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus, Human*
  • United States / epidemiology

Substances

  • Palivizumab